Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Vitamin D Levels and the Risk of Mortality in the General Population

    Correlating the findings in the 13,331 adults 20 years or older in the Third National Health and Nutrition Examination Survey (NHANES III) revealed that vitamin D deficiency is a risk factor for developing cardiovascular disease and is associated with increased all-cause mortality.
  • Pharmacology Watch

    Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
  • Clinical Briefs By Louis Kuritzky, MD

    Opinions on the consequences of marijuana use are wide-ranging: Some experts express grave concern that it may induce COPD, increase risk of lung cancer, promote the emergence of schizophrenia, and lead to "heavy drug" use; others essentially dismiss these (potential) adversities as inadequately established to permit accusations that marijuana has any commonplace serious adverse effects.
  • Human Papillomavirus Quadrivalent Recombinant Vaccine (Gardasil®)

    The FDA has extended the approval for the Human Papillomavirus Quadrivalent Recombinant Vaccine to include the prevention of vaginal and vulvar cancer. The vaccine, originally approved in 2006, is already approved for the prevention of cervical cancer and genital warts.
  • An Update on Tiotropium for Chronic Obstructive Pulmonary Disease

    Among almost 6000 patients with COPD who were using other classes of respiratory therapies, the addition of tiotropium, compared with placebo, was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period, but did not result in benefits in the rate of decline in FEV1.
  • FDA Notifications

    FDA approves generic lamivudine: On Oct. 7, 2008, the FDA granted tentative approval for a generic formulation of lamivudine 150 mg and 300 mg tablets, manufactured by Macleods Pharmaceuticals Limited of Daman, India, indicated for use in combination with other anti-retroviral drugs for the treatment of HIV-1 infection.
  • Time to step up HIV testing in women

    Review the last three patient charts: a 19-year-old college student, a 26-year-old mother of two, and a 43-year-old woman who is newly divorced. Which women were offered screening for HIV?
  • Making grant $ stretch through networking

    A New York City AIDS organization has demonstrated for years how to stretch funding and make programs more effective through a combination of collaborative meetings, networking, and volunteers.
  • Yes we can? Obama's win brings hope to HIV/AIDS groups

    Next month a new administration will usher in great expectations with regard to how President-elect Barack Obama will fund a variety of domestic programs, including HIV/AIDS prevention and medical care.
  • Full December 2008 Issue in PDF